144 related articles for article (PubMed ID: 35801818)
1. Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2'-MOE and Phosphorothioate Modified Antisense Oligonucleotides.
Wang Y; Diep JK; Yu RZ; Hurh E; Karwatowska-Prokopczuk E; Schneider E; Henry S; Bhanot S; Geary RS
J Clin Pharmacol; 2023 Jan; 63(1):21-28. PubMed ID: 35801818
[TBL] [Abstract][Full Text] [Related]
2. Integrated Assessment of the Clinical Performance of GalNAc
Crooke ST; Baker BF; Xia S; Yu RZ; Viney NJ; Wang Y; Tsimikas S; Geary RS
Nucleic Acid Ther; 2019 Feb; 29(1):16-32. PubMed ID: 30570431
[TBL] [Abstract][Full Text] [Related]
3. Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.
Yu RZ; Gunawan R; Post N; Zanardi T; Hall S; Burkey J; Kim TW; Graham MJ; Prakash TP; Seth PP; Swayze EE; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2016 Dec; 26(6):372-380. PubMed ID: 27500733
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice.
Prakash TP; Graham MJ; Yu J; Carty R; Low A; Chappell A; Schmidt K; Zhao C; Aghajan M; Murray HF; Riney S; Booten SL; Murray SF; Gaus H; Crosby J; Lima WF; Guo S; Monia BP; Swayze EE; Seth PP
Nucleic Acids Res; 2014 Jul; 42(13):8796-807. PubMed ID: 24992960
[TBL] [Abstract][Full Text] [Related]
5. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry
Zanardi TA; Korbmacher B; Boone L; Engelhardt JA; Wang Y; Burel S; Prill B; Aghajan M; Guo S; Henry SP
J Pharmacol Exp Ther; 2021 Apr; 377(1):51-63. PubMed ID: 33431610
[TBL] [Abstract][Full Text] [Related]
6. Characterization of the Activity and Distribution of a 2'-O-Methoxyethyl-Modified Antisense Oligonucleotide in Models of Acute and Chronic Kidney Disease.
Donner AJ; Bell TA; Greenlee S; Graham MJ; Crooke RM
Nucleic Acid Ther; 2018 Oct; 28(5):297-306. PubMed ID: 30133341
[TBL] [Abstract][Full Text] [Related]
7. Tissue pharmacokinetics of antisense oligonucleotides.
Bäckström E; Bonetti A; Johnsson P; Öhlin S; Dahlén A; Andersson P; Andersson S; Gennemark P
Mol Ther Nucleic Acids; 2024 Mar; 35(1):102133. PubMed ID: 38419941
[TBL] [Abstract][Full Text] [Related]
8. Comparative Characterization of Hepatic Distribution and mRNA Reduction of Antisense Oligonucleotides Conjugated with Triantennary N-Acetyl Galactosamine and Lipophilic Ligands Targeting Apolipoprotein B.
Watanabe A; Nakajima M; Kasuya T; Onishi R; Kitade N; Mayumi K; Ikehara T; Kugimiya A
J Pharmacol Exp Ther; 2016 May; 357(2):320-30. PubMed ID: 26907624
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotides: absorption, distribution, metabolism, and excretion.
Shadid M; Badawi M; Abulrob A
Expert Opin Drug Metab Toxicol; 2021 Nov; 17(11):1281-1292. PubMed ID: 34643122
[TBL] [Abstract][Full Text] [Related]
10. Assessment of the Drug Interaction Potential of Unconjugated and GalNAc
Shemesh CS; Yu RZ; Warren MS; Liu M; Jahic M; Nichols B; Post N; Lin S; Norris DA; Hurh E; Huang J; Watanabe T; Henry SP; Wang Y
Mol Ther Nucleic Acids; 2017 Dec; 9():34-47. PubMed ID: 29246313
[TBL] [Abstract][Full Text] [Related]
11. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
[TBL] [Abstract][Full Text] [Related]
12. Co-Administration of an Excipient Oligonucleotide Helps Delineate Pathways of Productive and Nonproductive Uptake of Phosphorothioate Antisense Oligonucleotides in the Liver.
Donner AJ; Wancewicz EV; Murray HM; Greenlee S; Post N; Bell M; Lima WF; Swayze EE; Seth PP
Nucleic Acid Ther; 2017 Aug; 27(4):209-220. PubMed ID: 28448194
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides.
Wada S; Yasuhara H; Wada F; Sawamura M; Waki R; Yamamoto T; Harada-Shiba M; Obika S
J Control Release; 2016 Mar; 226():57-65. PubMed ID: 26855051
[TBL] [Abstract][Full Text] [Related]
14. Chronic Toxicity Assessment of 2'-O-Methoxyethyl Antisense Oligonucleotides in Mice.
Zanardi TA; Kim TW; Shen L; Serota D; Papagiannis C; Park SY; Kim Y; Henry SP
Nucleic Acid Ther; 2018 Aug; 28(4):233-241. PubMed ID: 29708844
[TBL] [Abstract][Full Text] [Related]
15. Safety and Tolerability of GalNAc
Baker BF; Xia S; Partridge W; Engelhardt JA; Tsimikas S; Crooke ST; Bhanot S; Geary RS
Nucleic Acid Ther; 2024 Feb; 34(1):18-25. PubMed ID: 38227794
[TBL] [Abstract][Full Text] [Related]
16. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.
Shen W; De Hoyos CL; Migawa MT; Vickers TA; Sun H; Low A; Bell TA; Rahdar M; Mukhopadhyay S; Hart CE; Bell M; Riney S; Murray SF; Greenlee S; Crooke RM; Liang XH; Seth PP; Crooke ST
Nat Biotechnol; 2019 Jun; 37(6):640-650. PubMed ID: 31036929
[TBL] [Abstract][Full Text] [Related]
17. In vitro metabolism of 2'-ribose unmodified and modified phosphorothioate oligonucleotide therapeutics using liquid chromatography mass spectrometry.
Kim J; El Zahar NM; Bartlett MG
Biomed Chromatogr; 2020 Jul; 34(7):e4839. PubMed ID: 32246854
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic-pharmacodynamic modeling for reduction of hepatic apolipoprotein B mRNA and plasma total cholesterol after administration of antisense oligonucleotide in mice.
Shimizu R; Kitade M; Kobayashi T; Hori S; Watanabe A
J Pharmacokinet Pharmacodyn; 2015 Feb; 42(1):67-77. PubMed ID: 25376372
[TBL] [Abstract][Full Text] [Related]
19. Interspecies Scaling of Human Clearance and Plasma Trough Exposure for Antisense Oligonucleotides: A Retrospective Analysis of GalNAc3-Conjugated and Unconjugated-Antisense Oligonucleotides.
Nanavati C; McMullen G; Yu R; Geary RS; Henry SP; Wang Y
Nucleic Acid Ther; 2021 Aug; 31(4):298-308. PubMed ID: 33891483
[TBL] [Abstract][Full Text] [Related]
20. Integrated Assessment of Phase 2 Data on GalNAc
Baker BF; Xia S; Partridge W; Kwoh TJ; Tsimikas S; Bhanot S; Geary RS
Nucleic Acid Ther; 2023 Jan; 33(1):72-80. PubMed ID: 36454263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
